Trial Profile
Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 25 Feb 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Pooled analysis of 2 studies of 12 patients (NCT01866293 and NCT01582295) published in the Blood.
- 24 Aug 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov.